Phytopharm sees some hope in fight against Lou Gherig's disease
FTSE fledgling Phytopharm yesterday announced that a drug which originates from a traditional Chinese herbal remedy may provide hope for those suffering from motor neuron disease.
FTSE fledgling Phytopharm yesterday announced that a drug which originates from a traditional Chinese herbal remedy may provide hope for those suffering from motor neuron disease.
The drug development company said that early-stage tests in laboratory animals showed that the molecule under study, Cogane, had an impact in treating amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease, also widely known as Lou Gehrig's disease.
Cogane is already in use against Parkinson's.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
As of 09:18 am shares of Phytopharm are rising by 1.62% to 9.4p.
AB
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Six out of 10 retirees who accessed a pension didn’t use Pension Wise - how does the guidance service work?
Many pension savers don’t bother using the free government-backed service Pension Wise. So, how does it work, and could it be useful for you?
-
UK-EU trade deal: Britain to get a £9bn boost to the economy by 2040
The government’s agreement with the EU follows on from separate deals with India and the United States. Will it breathe life into the UK economy?